PHARMACOLOGICAL CORRECTION OF ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HYPERTENSION
Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD), among which hypertension (H) is the most common. The aim of the study was to assess the possibility of pharmacological correction of combined therapy with rituximab (RTM) and subcutaneous methotrexate (MTD) arterial stiffness in patients with RA in combination with H. 205 patients with the established diagnosis of RA among whom there were persons with H of the 2nd degree are surveyed. Was increasing the initial index values AIp75, SI, RI and the daily index AIp all patients with low-positive (lpRA) and high-positive RA (hpRA), and in combination with H 2 degrees, compared to the control group. Pharmacological correction of MTD in combination with RTM led to a decrease in stiffness indices in both lpRA and hpRA. In patients with RA and comorbid pathology improvement of arterial stiffness occurred in the initial moderate endothelial dysfunction (ED), and in severe - improvement was less significant. Pharmacological intervention with the use of RTM and MTD in the greatest degree effective when unexpressed endothelial disorders.